Navigation Links
Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
Date:6/24/2013

THE WOODLANDS, Texas, June 24, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented the first publication of data on LX2761 at the 73rd Scientific Sessions of the American Diabetes Association (ADA) in Chicago, on June 23, 2013.

David Powell, M.D., Lexicon's senior vice president of metabolism research, delivered an oral presentation titled "LX2761, an SGLT1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice."  Dr. Powell's presentation described the effects of LX2761 treatment on blood sugar control in mice with diabetes.

"LX2761 was designed to act locally in the gastrointestinal tract to reduce glucose absorption by inhibiting SGLT1 without any significant inhibition of SGLT2 in the kidney," said Alan Main, Ph.D., Lexicon's executive vice president of pharmaceutical research.  "This was accomplished through a dedicated medicinal chemistry effort to identify molecules with limited systemic exposure that showed efficacy in animal models of diabetes."

Consistent with design goals for an SGLT1 inhibitor without systemic exposure, LX2761 resulted in no urinary glucose excretion in mice while showing delayed intestinal glucose absorption and increased postprandial GLP-1 levels in mice, both alone and synergistically with the DPP-4 inhibitor sitagliptin. Notably, blood glucose excursions after an oral glucose challenge were still decreased 15 hours after oral LX2761 administration. Finally, LX2761 improved glycemic control in STZ-diabetic mice and in the KKAy mouse model of type 2 diabetes, as measured by reductions in hemoglobin A1c and oral glucose tol
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
2. Lexicon To Present At The Jefferies Global Healthcare Conference
3. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
5. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
6. Lexicon to Report First Quarter Financial Results on May 10, 2013
7. Lexicon To Present At The Needham Healthcare Conference
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
9. Lexicon To Present At The BIO CEO & Investor Conference
10. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
11. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Switzerland, September 15, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 14 ThermoGenesis Corp. (Nasdaq: KOOLD ), a ... store adult stem cells, said today that revenues for the ... of $4.0 million for the same quarter a year ago. ... million. The Company recorded disposable revenues of $4.8 ...
Cached Medicine Technology:ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 2ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 3ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 4ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 5ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 6ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 7ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 2ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 3ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 4ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 5ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 6ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 7
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... By Amy Norton ... -- Yoga has long been believed to improve overall health, ... may also help the heart, a new review finds. ... exercise such as brisk walking, said lead researcher Paula Chu, ... Boston. The review, of 37 clinical trials, found that ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... , Jan. 28 Code Hennessy & Simmons ... portfolio investment of CHS Private Equity V LP and Linden ... private equity firm.   , Suture Express is a distributor ... products.  Suture Express offers over 1,600 acute care hospitals and ...
... used with chemo for HER2 malignancies, researchers report , ... patients with HER2-positive tumors benefit from receiving the targeted ... "It,s in a European journal [The Lancet], but it,s ... begun to do," said Dr. Jay Brooks, chairman of ...
... , DENVER , Jan. 28 ... it has entered into an agreement to acquire Highlands Ranch ... the Denver suburb of Highlands Ranch . ... satisfaction of other requirements as detailed in the agreement.   ...
... Jan. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... Each of the dividends will be $0.50 per share. The first ... stockholders who own shares of PDL on March 15, 2010 , the ... 2010 to all stockholders who own shares of PDL on September ...
... , DETROIT , Jan. 28 Caraco Pharmaceutical ... $52.0 million and $178.4 million for the ... to $55.7 million and $286.2 million , respectively, ... the third quarter and first nine months of Fiscal 2010, in ...
... trigger a medical evaluation for ovarian cancer does not appear ... in diagnosis in only 1 out of 100 women in ... published online January 28 in the Journal of the ... Hutchinson Cancer Research Center in Seattle assessed the predictive value ...
Cached Medicine News:Health News:Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc. 2Health News:Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc. 3Health News:Herceptin Again Proves Mettle Against Breast Cancer 2Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 2Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 3Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 4Health News:PDL BioPharma Announces Two $0.50 Dividends in 2010 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 8Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 9Health News:Symptoms have little value for early detection of ovarian cancer 2
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
For general purposes...
... BcMag Streptavidin magnetic beads are ... of biotinylated molecules such as ... from cell lysates or hybridization ... highly dispersed, it can also ...
Medicine Products: